See feature articles below: (SKLN: SFOR: NWBO: AMRN)

About Broad Street Alerts:
Big opportunities in Small Cap’s

Broad Street Alerts recent profiles and track record, 217% in verifiable potential gains for our members on the last 4 small cap alerts alone!

February 10th, 2016- (NASDAQ: BONT) opened $1.65/share hit a high of $3.00/share within 30 days our member potential gains- 83%

March 7th, 2016-(NYSE-MKT: FSI) opened at .91/share and hit 1.10/share within 5 days for gains of 21% for our members.

March 24th, 2016- (NASDAQ: ICLD) opened at $.77/share it a high of $1.15/share within 2 days for gains of 49% for our members.

April 11th, 2016 – (NASDAQ: FNJN) called at $1.07/share hit $1.76/share in 3 days for 64% gains for our members.
These are numbers that make traders drool. Any trader in any market would fall all over themselves to see numbers like this. So if you’ve been on the fence, perhaps it’s time to start doing some research and verify our numbers for yourself. We are constantly raising the bar and separate ourselves from the rest of the small-cap newsletters as the best in business.

We know with a large following comes a large responsibility as we have everyone from institutional investors to the beginner following our profiled securities in our newsletters. This is something we take very seriously always seeking small cap growth companies that have both near and long-term potential for our members.

***Get our small cap profiles, special situation and watch alerts in real time. We are now offering our VIP SMS/text alert service for free, simply text the word “Alerts” to the phone number 25827 from your cell phone.
Full Report (NASDAQ:SKLN)

Skyline Medical Inc (SKLN) has received overwhelmingly positive real-world cost savings and safety feedback for its flagship product, the STREAMWAY System®, from Tucson Medical Center’s (“TMC”) Radiology department, which was included in a case study issued earlier this month.

According to TMC, the STREAMWAY System allows their radiology department to lower waste fluid disposal costs per procedure by 77.6% to $24.00, an impressive decrease from the $107.10 TMC was spending on each procedure using evacuated bottles. As a result, TMC was able to report an ROI in the first nine months of utilizing the STREAMWAY System since being installed in 2015, and anticipates a cost savings for the 1 system currently installed of $22,140 annually.

Source: News Oracle
Full Report (OTCMKT: SFOR)

On4/13/2016, shares of Strikeforce Technologies Inc (OTCMKTS:SFOR) unchanged +0.0000% in trading session and finally closed at $0.0022. The company most recent volume stood at 307.36 million shares as compared to its average volume of 199.5 thousand shares. Over the one year trading period, the stock has a high price of $390.0000 and its low is recorded at $0.0018. The company has a market cap of $23236.40.

Due to negative move, the stock’s recent closing price is lower than its previous close of $0.0022.

During the last trading period, the peak price level of the share was $0.0027; it means it is top price of day and down price level of the share was $0.0018; it means minimum price of the day at which share is traded.

The share price showed down trend from its 200 days moving average of $0.1225 with -98.2038% and highlighted negative move of -61.9998% from 50 days moving average of $0.0058.

StrikeForce Technologies, Inc. operates as a software development and services company in the United States and internationally.

Source: Street Updates
Full Report (NASDAQ: NWBO)

The different research groups’ active in the market deploys their terminology for giving their Buy/Sell recommendations. Investors not accustomed with a particular broker could find the buy/sell recommendations tough to interpret. To solve this problem, Zacks lists an analyst brokerage rating on a 1 to 5 sliding scale. If the rating is one, it is stated as buy recommendation, while five is known as Strong Sell.

Brokerages maintain a strong outlook on Northwest Biotherapeutics, Inc. (NASDAQ:NWBO) shares. Based on the Zacks poll results, as of 2016-04-17, the stock has an ABR of 1 rating. This number highlights the scoring on a 1 to 5 scale, where 1 implies Strong Buy and 5 indicates a Strong Sell. Zacks included as many as 1 sell-side firms in its poll.

Technical Analysis is the thorough study of supply and demand in the market. It is done by comparing the stock price movements and the number of shares traded. Understanding the price movement about the High, Open, Low and Closing Prices of stock on a given minute, hour, month, day, or week and comparing with volume offers an insight of future market direction.

Analysts give price targets by technical analysis. It can be defined as a projected price level by an investment analyst. An estimate that, if achieved, results in a trader knowing the best possible outcome for investments. It is the looked on the level at which the trader would book profits in existing position.

The brokerages have a one-year mean price target of $8 for Northwest Biotherapeutics, Inc. (NASDAQ:NWBO) stock while the median stock price estimate is $8. The highest price estimate is $8 while the lowest price target is $8. The standard deviation of given estimates is 0.

Source: Realist Investor
Full Report (NASDAQ:AMRN)

Balyasny Asset Management LLC raised its position in shares of Amarin Co. plc (NASDAQ:AMRN) by 101.9% during the fourth quarter, according to its most recent filing with the SEC. The fund owned 2,110,357 shares of the biopharmaceutical company’s stock after buying an additional 1,065,357 shares during the period. Balyasny Asset Management LLC owned approximately 1.15% of Amarin Co. plc worth $3,989,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. Clearbridge LLC boosted its stake in Amarin Co. plc by 3.9% in the fourth quarter. Clearbridge LLC now owns 2,004,747 shares of the biopharmaceutical company’s stock worth $3,789,000 after buying an additional 75,020 shares during the period. OppenheimerFunds Inc. boosted its stake in Amarin Co. plc by 0.5% in the fourth quarter. OppenheimerFunds Inc. now owns 5,323,360 shares of the biopharmaceutical company’s stock worth $10,061,000 after buying an additional 27,090 shares during the period. Tamarack Advisers LP acquired a new stake in Amarin Co. plc during the fourth quarter worth $10,395,000. Finally, Oracle Investment Management Inc. boosted its stake in Amarin Co. plc by 9.4% in the fourth quarter.

Oracle Investment Management Inc. now owns 6,645,793 shares of the biopharmaceutical company’s stock worth $12,561,000 after buying an additional 568,915 shares during the period.
Shares of Amarin Co. plc (NASDAQ:AMRN) opened at 1.74 on Thursday. Amarin Co. plc has a 12-month low of $1.24 and a 12-month high of $2.80. The stock’s 50 day moving average price is $1.54 and its 200 day moving average price is $1.73. The firm’s market capitalization is $318.99 million.
Amarin Co. plc (NASDAQ:AMRN) last issued its quarterly earnings results on Thursday, February 25th. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.03. During the same period in the previous year, the company posted ($0.11) earnings per share. The business had revenue of $26.40 million for the quarter, compared to analyst estimates of $23.62 million. The business’s revenue for the quarter was up 61.4% on a year-over-year basis. Equities research analysts expect that Amarin Co. plc will post ($0.38) earnings per share for the current year.
Several research analysts have weighed in on the company. HC Wainwright reiterated a “buy” rating and set a $10.00 price objective on shares of Amarin Co. plc in a research report on Friday, February 26th. Zacks Investment Research upgraded Amarin Co. plc from a “sell” rating to a “hold” rating in a research report on Wednesday, January 6th.
In other Amarin Co. plc news, CEO John F. Thero purchased 25,000 shares of Amarin Co. plc stock in a transaction dated Monday, February 1st. The shares were acquired at an average cost of $1.37 per share, with a total value of $34,250.00. Following the completion of the transaction, the chief executive officer now owns 661,743 shares in the company, valued at approximately $906,587.91. The transaction was disclosed in a filing with the SEC, which is available at this link.
Amarin Corporation plc (NASDAQ:AMRN) is a biopharmaceutical company. The Company is engaged in the commercialization and development of therapeutics for cardiovascular health. Amarin’s lead product, Vascepa (icosapent ethyl) capsules, are used as an adjunct to diet to reduce triglyceride levels in adult patients with severe (triglyceride or TG over 500 milligrams per deciliter) hypertriglyceridemia.

Source:Ticker report
Broad street alerts has not been compensated for the mention of any publicly traded companies in this article with exception to FNJN.

Broad Street Alerts was previously compensated eighteen thousand five hundred dollars by star media llc for the mention of FNJN however, that contract has expired.

See feature article below:

About Broad Street Alerts:
Big opportunities in Small Cap’s

Broad Street Alerts recent profiles and track record, 217% in verifiable potential gains for our members on the last 4 small cap alerts alone!

February 10th, 2016- (NASDAQ: BONT) opened $1.65/share hit a high of $3.00/share within 30 days our member potential gains- 83%

March 7th, 2016-(NYSE-MKT: FSI) opened at .91/share and hit 1.10/share within 5 days for gains of 21% for our members.

March 24th, 2016- (NASDAQ: ICLD) opened at $.77/share it a high of $1.15/share within 2 days for gains of 49% for our members.

April 11th, 2016 – (NASDAQ: FNJN) called at $1.07/share hit $1.76/share in 3 days for 64% gains for our members.
These are numbers that make traders drool. Any trader in any market would fall all over themselves to see numbers like this. So if you’ve been on the fence, perhaps it’s time to start doing some research and verify our numbers for yourself. We are constantly raising the bar and separate ourselves from the rest of the small-cap newsletters as the best in business.

We know with a large following comes a large responsibility as we have everyone from institutional investors to the beginner following our profiled securities in our newsletters. This is something we take very seriously always seeking small cap growth companies that have both near and long-term potential for our members.

***Get our small cap profiles, special situation and watch alerts in real time. We are now offering our VIP SMS/text alert service for free, simply text the word “Alerts” to the phone number 25827 from your cell phone.
Article:

General Cannabis Corp (OTCMKTS:CANN) has announced the launch of its public market research service division. The new division would be called General Cannabis Equity Research. The CEO of CANN, Robert Frichtel, labeled the development of the division as the first step, in the development of a research division, which makes use of the company’s position to gain market insight. He was of the opinion that the GCER would be invaluable in making investment decisions. The CEO also clarified that the shear breadth of the company’s corporate presence would be enough to provide GCER, with unique and valuable insight.

The executive chairman of General Cannabis, Michael Feinsod, stressed on the absence of an equity research firm in the cannabis sector. He claimed that while there were several publicly traded companies in this space, there are no reliable sources for information on them. The chairman was of the opinion that this void tends to limit public access to the industry and also limits the financing options for them. He confirmed that the division would be official launched by July 1 and the company was currently hiring experts for the division.

The chairman also revealed that the division would focus on intrinsic value and quality of management at the companies for their reports. He further claimed that company positions would be evaluated based on market dynamics and scenario. The first report will be issued in Jul 2016 and would only focus on companies that are current with their filings and have reported their quarter up to March 31 2016. The chairman also referred to the legalization of cannabis and stated that it was an exciting time for investors to get involved in the industry. It should be noted here that CANN is an all in one resource for regulated cannabis service providers. It manufactures and markets the highest quality of cannabis to consumers.

General Cannabis Corp (OTCMKTS:CANN) gained 13.30% in terms of share value, during the April 14 trading session, to close at a share price of $1.27.

Source: MMJ Reporter

 

 
Broad street alerts has not been compensated for the mention of any publicly traded companies in this article with exception to FNJN.

Broad Street Alerts was previously compensated eighteen thousand five hundred dollars by star media llc for the mention of FNJN however, that contract has expired.

See feature article below:

About Broad Street Alerts:
Big opportunities in Small Cap’s

Broad Street Alerts recent profiles and track record, 217% in verifiable potential gains for our members on the last 4 small cap alerts alone!

February 10th, 2016- (NASDAQ: BONT) opened $1.65/share hit a high of $3.00/share within 30 days our member potential gains- 83%

March 7th, 2016-(NYSE-MKT: FSI) opened at .91/share and hit 1.10/share within 5 days for gains of 21% for our members.

March 24th, 2016- (NASDAQ: ICLD) opened at $.77/share it a high of $1.15/share within 2 days for gains of 49% for our members.

April 11th, 2016 – (NASDAQ: FNJN) called at $1.07/share hit $1.76/share in 3 days for 64% gains for our members.
These are numbers that make traders drool. Any trader in any market would fall all over themselves to see numbers like this. So if you’ve been on the fence, perhaps it’s time to start doing some research and verify our numbers for yourself. We are constantly raising the bar and separate ourselves from the rest of the small-cap newsletters as the best in business.

We know with a large following comes a large responsibility as we have everyone from institutional investors to the beginner following our profiled securities in our newsletters. This is something we take very seriously always seeking small cap growth companies that have both near and long-term potential for our members.

***Get our small cap profiles, special situation and watch alerts in real time. We are now offering our VIP SMS/text alert service for free, simply text the word “Alerts” to the phone number 25827 from your cell phone.
Article:

The different research groups’ active in the market deploys their terminology for giving their Buy/Sell recommendations. Investors not accustomed with a particular broker could find the buy/sell recommendations tough to interpret. To solve this problem, Zacks lists an analyst brokerage rating on a 1 to 5 sliding scale. If the rating is one, it is stated as buy recommendation, while five is known as Strong Sell.

Brokerages maintain a strong outlook on Uni-Pixel, Inc. (NASDAQ:UNXL) shares. Based on the Zacks poll results, as of 2016-04-16, the stock has an ABR of 2 rating. This number highlights the scoring on a 1 to 5 scale, where 1 implies Strong Buy and 5 indicates a Strong Sell. Zacks included as many as 2 sell-side firms in its poll.

Technical Analysis is the thorough study of supply and demand in the market. It is done by comparing the stock price movements and the number of shares traded. Understanding the price movement about the High, Open, Low and Closing Prices of stock on a given minute, hour, month, day, or week and comparing with volume offers an insight of future market direction.

Analysts give price targets by technical analysis. It can be defined as a projected price level by an investment analyst. An estimate that, if achieved, results in a trader knowing the best possible outcome for investments. It is the looked on the level at which the trader would book profits in existing position.

The brokerages have a one-year mean price target of $3.5 for Uni-Pixel, Inc. (NASDAQ:UNXL) stock while the median stock price estimate is $3.5. The highest price estimate is $6 while the lowest price target is $1. The standard deviation of given estimates is 3.535.
Source:Enterprise Leader

Broad street alerts has not been compensated for the mention of any publicly traded companies in this article with exception to FNJN.

Broad Street Alerts was previously compensated eighteen thousand five hundred dollars by star media llc for the mention of FNJN however, that contract has expired.

See feature article below:

About Broad Street Alerts:
Big opportunities in Small Cap’s

Broad Street Alerts recent profiles and track record, 217% in verifiable potential gains for our members on the last 4 small cap alerts alone!

February 10th, 2016- (NASDAQ: BONT) opened $1.65/share hit a high of $3.00/share within 30 days our member potential gains- 83%

March 7th, 2016-(NYSE-MKT: FSI) opened at .91/share and hit 1.10/share within 5 days for gains of 21% for our members.

March 24th, 2016- (NASDAQ: ICLD) opened at $.77/share it a high of $1.15/share within 2 days for gains of 49% for our members.

April 11th, 2016 – (NASDAQ: FNJN) called at $1.07/share hit $1.76/share in 3 days for 64% gains for our members.
These are numbers that make traders drool. Any trader in any market would fall all over themselves to see numbers like this. So if you’ve been on the fence, perhaps it’s time to start doing some research and verify our numbers for yourself. We are constantly raising the bar and separate ourselves from the rest of the small-cap newsletters as the best in business.

We know with a large following comes a large responsibility as we have everyone from institutional investors to the beginner following our profiled securities in our newsletters. This is something we take very seriously always seeking small cap growth companies that have both near and long-term potential for our members.

***Get our small cap profiles, special situation and watch alerts in real time. We are now offering our VIP SMS/text alert service for free, simply text the word “Alerts” to the phone number 25827 from your cell phone.
Article:

Amedica Corporation (Nasdaq: AMDA) announced a partnership with Shandong Weigao Orthopedic Device Company Limited (“Weigao Orthopedic”), a subsidiary of Shandong Weigao Group Medical Polymer Company Limited (HKSE: 1066), a medical device company in China specializing in the R&D, production and sale of spine, trauma and joint orthopedic implants.

Under the distribution agreement, Weigao Orthopedic will have exclusive rights for the sale, marketing and distribution of Amedica-branded silicon nitride spinal implants in the People’s Republic of China, and will abide by minimum annual purchase requirements in Year 1 of 20,000 units, growing annually to 50,000 units in Year 6, following regulatory clearance by the China Food and Drug Administration (CFDA). Weigao Orthopedic will leverage its expertise in acquiring CFDA clearance of medical devices, in order to accelerate Chinese clearance of Amedica’s products.

“With more than 50,000 minimum unit sales to occur within the first two years following CFDA clearance, this agreement far surpasses total silicon nitride unit sales to-date, and marks a momentous time for Amedica,” said Dr. Sonny Bal, Chairman and Chief Executive Officer. “This partnership with Weigao Orthopedic allows us to significantly increase our global sales footprint with a large-scale distribution partner who is familiar with the Chinese regulatory landscape. Weigao Orthopedic’s expertise in sales and distribution is an excellent fit for our innovative silicon nitride technology platform. We look forward to this key strategic partnership to distribute our silicon nitride technology into Asian markets that are particularly receptive to bioceramic implants.”

“We are very pleased with this exclusive distributor partnership as we plan to leverage the Amedica brand to offer a truly differentiated product to our broad network of hospitals and medical units in China,” stated Mr. Gong Jianbo, Chief Executive Officer and Executive Director of Weigao Orthopedic. “We expect the combination of this technically advanced biomaterial with our well-established network to quickly gain significant market share. We also look forward to expanding our partnership beyond spine products and into hip and knee applications. Weigao Orthopedic is well positioned to facilitate the approval and commercial launch of Amedica’s silicon nitride spinal fusion devices in one of the world’s largest healthcare markets.”

Source:Street Insider

Broad street alerts has not been compensated for the mention of any publicly traded companies in this article with exception to FNJN.

Broad Street Alerts was previously compensated eighteen thousand five hundred dollars by star media llc for the mention of FNJN however, that contract has expired.

See feature article below:

About Broad Street Alerts:
Big opportunities in Small Cap’s

Broad Street Alerts recent profiles and track record, 217% in verifiable potential gains for our members on the last 4 small cap alerts alone!

February 10th, 2016- (NASDAQ: BONT) opened $1.65/share hit a high of $3.00/share within 30 days our member potential gains- 83%

March 7th, 2016-(NYSE-MKT: FSI) opened at .91/share and hit 1.10/share within 5 days for gains of 21% for our members.

March 24th, 2016- (NASDAQ: ICLD) opened at $.77/share it a high of $1.15/share within 2 days for gains of 49% for our members.

April 11th, 2016 – (NASDAQ: FNJN) called at $1.07/share hit $1.76/share in 3 days for 64% gains for our members.
These are numbers that make traders drool. Any trader in any market would fall all over themselves to see numbers like this. So if you’ve been on the fence, perhaps it’s time to start doing some research and verify our numbers for yourself. We are constantly raising the bar and separate ourselves from the rest of the small-cap newsletters as the best in business.

We know with a large following comes a large responsibility as we have everyone from institutional investors to the beginner following our profiled securities in our newsletters. This is something we take very seriously always seeking small cap growth companies that have both near and long-term potential for our members.

***Get our small cap profiles, special situation and watch alerts in real time. We are now offering our VIP SMS/text alert service for free, simply text the word “Alerts” to the phone number 25827 from your cell phone.
Article:

On 4/15/2016, shares of Repros Therapeutics Inc. (NASDAQ:RPRX) fell -14.98% in trading session and finally closed at $2.27. The company most recent volume stood at 8.05 million shares as compared to average volume of 1.83 million shares. Over the one year trading period, the stock has a high price of $8.96 and its low price is recorded at $0.80. The company has a market cap of $55.20M.

During the last trading period, the peak price level of the share was $2.58; it means it is top price of day and down price level of the share was $2.16; it means minimum price of the day at which price share traded.

The corporation generated income of $ 29.20M. The year-to-date performance of the company stands at 87.60 % with increase of 152.22 % in the last week and 118.27 % in the previous three months.

What Analysts Say about Repros Therapeutics Inc.:

The stock has received rating from many Reuters analysts. Currently shares have been rated as “Buy” from 0 Analysts. 0 analysts have suggested “Sell” for the company. 2 analysts have rated the company as a strong “Hold”. Underperform rating was given by 0 analyst and Outperform rating was given by 1 analyst.

The Corporation has a Mean Rating of 2.67 based on the Reuters Analysts consensus issuing ratings.

HCA Holdings, Inc. (NYSE:HCA) showed bearish move with loss of -0.48% after exchanging volume of 3.75 million shares in last trading session ended on 4/15/2016. The company recent traded volume was higher than its average volume of 3.31 million shares. HCA Holdings, Inc. has a P/E and EPS ratio of 16.10and 4.99, respectively. The stock has a consensus analyst price target of $88.36for twelve month. The company finished it is trading at $80.33.

During the 52-week period, the peak price level of the share was observed at $95.49; this is higher price of share and down price level of the share was seen at $43.91; this is lower price at which share is traded.

The company has shown climb of 1.50 % in past 5 days with YTD performance of 18.78 % and 3-month performance up 23.36 %. Net profit margin of the company was 5.40 % while gross profit margin was 83.30 %. The beta value is 1.12.

What Analysts Say about this HCA Holdings, Inc.:

The stock has received rating from many Reuters analysts. Currently shares have been rated as “Buy” from 8 Analysts. 0 analysts have suggested “Sell” for the company. 6 analysts have rated the company as a strong “Hold”. Underperform rating was given by 0 analyst and Outperform rating was given by 10 analyst.

The Corporation has a Mean Rating of 1.92 based on the Reuters Analysts consensus issuing ratings.

Source: Street Updates

Broad street alerts has not been compensated for the mention of any publicly traded companies in this article with exception to FNJN.

Broad Street Alerts was previously compensated eighteen thousand five hundred dollars by star media llc for the mention of FNJN however, that contract has expired.